BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow-to-Debt Ratio
BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-62.14 Million could theoretically repay 0% of its total liabilities ($1.02 Billion) in one year. Explore investment intensity of BioCryst Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioCryst Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1994–2025)
Historical debt coverage capacity for BioCryst Pharmaceuticals Inc across 32 annual periods. Also explore BioCryst Pharmaceuticals Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BioCryst Pharmaceuticals Inc (1994–2025)
Year-by-year debt coverage analysis for BioCryst Pharmaceuticals Inc. For market capitalisation and broader financial context, see BCRX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.52x | $329.88 Million | $633.31 Million | ▲ +1067.6% |
| 2024 | -0.05x | $-52.02 Million | $966.35 Million | ▲ +45.0% |
| 2023 | -0.10x | $-95.14 Million | $972.49 Million | ▲ +48.9% |
| 2022 | -0.19x | $-161.85 Million | $844.60 Million | ▲ +6.3% |
| 2021 | -0.20x | $-142.16 Million | $695.14 Million | ▲ +47.2% |
| 2020 | -0.39x | $-137.22 Million | $353.98 Million | ▲ +40.7% |
| 2019 | -0.65x | $-89.58 Million | $137.03 Million | ▲ +31.1% |
| 2018 | -0.95x | $-92.56 Million | $97.61 Million | ▼ -117.8% |
| 2017 | -0.44x | $-41.14 Million | $94.49 Million | ▲ +28.1% |
| 2016 | -0.61x | $-53.44 Million | $88.27 Million | ▼ -254.6% |
| 2015 | -0.17x | $-13.12 Million | $76.83 Million | ▲ +72.9% |
| 2014 | -0.63x | $-38.55 Million | $61.24 Million | ▼ -18.6% |
| 2013 | -0.53x | $-26.53 Million | $49.99 Million | ▲ +17.8% |
| 2012 | -0.65x | $-37.40 Million | $57.89 Million | ▼ -35.0% |
| 2011 | -0.48x | $-32.25 Million | $67.40 Million | ▲ +26.4% |
| 2010 | -0.65x | $-28.55 Million | $43.94 Million | ▼ -124.1% |
| 2009 | -0.29x | $-16.22 Million | $55.92 Million | ▲ +46.8% |
| 2008 | -0.55x | $-20.87 Million | $38.27 Million | ▼ -69.8% |
| 2007 | -0.32x | $-25.00 Million | $77.81 Million | ▲ +0.0% |
| 2006 | -0.32x | $-15.21 Million | $47.33 Million | ▲ +43.8% |
| 2005 | -0.57x | $-23.35 Million | $40.81 Million | ▲ +90.1% |
| 2004 | -5.79x | $-18.15 Million | $3.13 Million | ▲ +14.7% |
| 2003 | -6.79x | $-11.20 Million | $1.65 Million | ▲ +51.3% |
| 2002 | -13.96x | $-16.36 Million | $1.17 Million | ▼ -213.6% |
| 2001 | -4.45x | $-10.16 Million | $2.28 Million | ▼ -1208.9% |
| 2000 | -0.34x | $-3.18 Million | $9.35 Million | ▲ +86.1% |
| 1999 | -2.45x | $-4.90 Million | $2.00 Million | ▲ +18.3% |
| 1998 | -3.00x | $-4.20 Million | $1.40 Million | ▲ +65.0% |
| 1997 | -8.58x | $-10.30 Million | $1.20 Million | ▼ -114.6% |
| 1996 | -4.00x | $-6.80 Million | $1.70 Million | ▲ +6.5% |
| 1995 | -4.28x | $-7.70 Million | $1.80 Million | ▼ -5.3% |
| 1994 | -4.06x | $-6.50 Million | $1.60 Million | — |